Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by skibum45on Jul 29, 2019 8:40pm
197 Views
Post# 29972876

RE:A$$ u me!

RE:A$$ u me!don't think MM is pumping.... they're just trying to stimulate discussion and enthusiastic about prospects as a lot are. It's difficult to overstate the potential of Antibe if effectiveness proves similar to existing NSAIDs, favorable gastrointestinal profile persists, AND no significant new side effects discovered (eg. cardiac risk associated with some of the COX-2  inhibitors such as Vioxx). Apart from NSAIDs there are really very limited options for chronic pain. The ulcer risk has always been a massive roadblock for chronic NSAID use. Other drugs? ...acetaminophen --- mildly better than placebo... narcotics (including new synthetics like tramadol) -- addictive, tolerance inducing and simply don't work for chronic pain because of tolerance ... others such as gabapentin, pregabalin, duloxetine, etc. etc. are riddled with side effects and minimal evidence for benefit to a point that they will never be widely used. NSAIDs work.... just they destroy your stomach with chronic use. If ATE.V has solved (or even significantly improved) on this, the potential seems massive. Seems worth a stab to me. Excited to see the trial results.
Bullboard Posts